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Abstract
In bone, depletion of osteoclasts reduces bone formation in vivo, as does osteal macrophage depletion. How osteoclasts
and macrophages promote the action of bone forming osteoblasts is, however, unclear. Since recruitment and
differentiation of multi-potential stromal cells/mesenchymal stem cells (MSC) generates new active osteoblasts, we
investigated whether human osteoclasts and macrophages (generated from cord blood-derived hematopoietic progenitors)
induce osteoblastic maturation in adipose tissue-derived MSC. When treated with an osteogenic stimulus (ascorbate,
dexamethasone and b-glycerophosphate) these MSC form matrix-mineralising, alkaline phosphatase-expressing osteoblas-
tic cells. Cord blood-derived progenitors were treated with macrophage colony stimulating factor (M-CSF) to form immature
proliferating macrophages, or with M-CSF plus receptor activator of NFkB ligand (RANKL) to form osteoclasts; culture
medium was conditioned for 3 days by these cells to study their production of osteoblastic factors. Both osteoclast- and
macrophage-conditioned medium (CM) greatly enhanced MSC osteoblastic differentiation in both the presence and
absence of osteogenic medium, evident by increased alkaline phosphatase levels within 4 days and increased
mineralisation within 14 days. These CM effects were completely ablated by antibodies blocking gp130 or oncostatin M
(OSM), and OSM was detectable in both CM. Recombinant OSM very potently stimulated osteoblastic maturation of these
MSC and enhanced bone morphogenetic protein-2 (BMP-2) actions on MSC. To determine the influence of macrophage
activation on this OSM-dependent activity, CM was collected from macrophage populations treated with M-CSF plus IL-4 (to
induce alternative activation) or with GM-CSF, IFNc and LPS to cause classical activation. CM from IL-4 treated macrophages
stimulated osteoblastic maturation in MSC, while CM from classically-activated macrophages did not. Thus, macrophage-
lineage cells, including osteoclasts but not classically activated macrophages, can strongly drive MSC-osteoblastic
commitment in OSM-dependent manner. This supports the notion that eliciting gp130-dependent signals in human MSC
would be a useful approach to increase bone formation.
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Introduction
Osteoblasts are specialised bone forming cells that derive from
local mesenchymal progenitors through multi-step commitment
and maturation processes that are dependent on transcription
factors Runx2 and osterix [1]. Such progenitors include MSC
populations found in bone and in extraosseous tissues [2], highly
proliferative cells expressing CD73, CD90 and CD105 but lacking
hematopoietic markers [3,4]. When purified, these cells can form
functional osteoblasts both in vitro and in vivo [5–7] but also have
the capacity to form other types of stromal cells, such as adipocytes
[2,7,8]. While the MSC transition to osteoblasts is not fully
understood, the appropriate enhancement of such a process might
form the basis of therapies that increase bone formation in patients
with low bone mass.
Maintenance of bone strength requires bone remodelling,
whereby old or damaged bone is removed by osteoclasts
(multinucleated bone resorbing cells of the myelomonocytic
lineage) [9–11] and the bone removed by osteoclasts subsequently
replaced by osteoblast action. This, and the impairment of bone
formation following anti-osteoclastic therapies [12], suggest a
functional link between osteoclast and osteoblast activity. Howev-
er, osteoclast stimulation of mature osteoblast activity has not been
convincingly demonstrated. An alternative possibility is that
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osteoclasts exert their influence on osteoblast progenitors, such as
local MSC. Indeed, MSC are chemotactically attracted to bone
sites undergoing remodelling [13]. It is notable, however, that, not
all bone formation requires osteoclast action; osteal macrophages,
a locally resident CD11b+F4/80+ cell population closely related to
osteoclasts, also exert a significant regulatory influence on bone
formation [14,15]. Osteal macrophages are located in close
proximity to osteoblasts and their removal greatly decreases bone
formation [16], but the nature of their influence on osteoblasts is
also unclear. Macrophages display many diverse functions central
to innate immunity and adaptive immune responses, especially via
antigen presentation and cytokine production, but also play
regulatory and cytokine secretory roles in many tissues. Macro-
phages respond to environmental stimuli by altering their
behaviour and excitation states, notably their phenotype can be
polarised by Th1-cytokines towards classical activation and by
Th2-cytokines towards a number of alternative activation states.
An abundance of classically activated macrophages in the bone,
typically seen in inflammatory joint diseases, is generally associated
with impaired bone formation, perhaps related to suppression of
osteoblastic Wnt responses [17]. Therefore, understanding the
influence of macrophages in different activation states on
immature osteoblast-lineage cells is of great interest in bone
biology.
We have previously employed cord blood-derived immature
myelomonocytic-lineage cells rich in colony forming units (CFU)-
GM as an excellent source of human osteoclast-forming cells
[18,19]. Such cord blood mononuclear cells contain populations
broadly similar to immature myelomonocytic populations found in
bone marrow. They are a rich source of immature macrophages
that proliferate with M-CSF or GM-CSF treatment [18,20] and,
when treated with M-CSF plus RANKL, they form large numbers
of bone resorbing osteoclasts. Circulating adult CD14+ monocytes
also form osteoclasts with RANKL/M-CSF stimulus but do so far
more slowly and with much lower yield [20,21], reflecting their
preponderance of mature cells. We therefore employed the superior
cord blood-derived progenitors to generate both macrophages and
osteoclast-rich cultures to study their effects on osteoblastic
differentiation in human MSC. A related approach was employed
in the recent work of Guihard et al. [22] and Nicolaidou et al. [23]
who both found that CD14+ adult monocytes enhanced osteoblastic
differentiation of MSC in a manner at least partly dependent on the
IL-6 family cytokine oncostatin M (OSM). Their observations
differed in certain key respects, however. Guihard et al. [22] found
that medium conditioned by CD14+ (especially classically activated
CD14+ cells) strongly enhancedMSCmaturation, while Nicolaidou
et al. [23] observed macrophage-MSC contact was essential for such
pro-osteoblastic activity. While these are seminal pieces of work,
clearly further studies are needed that employ other macrophage
lineage cells that MSC encounter in bone. In our studies we found
that both cord-blood derived macrophage and osteoclast popula-
tions produce soluble factors that very rapidly (within 4 days) drive
osteoblastic maturation in these MSC populations. This activity was
dependent upon OSM secretion but neither cell contact nor
classical activation (in macrophages) was required for osteoblastic
maturation of MSC. This provides further evidence for the role of
osteoclasts, macrophages and OSM in the regulation of bone
metabolism.
Materials and Methods
Ethics Statement
Human umbilical cord blood and adipose tissue samples were
obtained with informed, written consent from healthy donors
under protocols approved by Barwon Health Human Research
and Ethics Committee.
Cell media and reagents
Eagle’s minimum essential medium (MEM), Dulbecco’s Modified
Eagle’s Medium (DMEM), penicillin/streptomycin solutions, para-
formaldehyde, Fast Garnet GBC, naphthol AS-BI-phosphate,
collagenase-type-1, p-nitrophenylphosphate, p-nitrophenyl, dietha-
nolamine, Alizarin Red, cetylpyridinium chloride, dexamethasone,
dimethyl sulphoxide (DMSO) and 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide, insulin, 3-Isobutyl-1-methylxanthine
(IBMX) and indomethacin were purchased from Sigma-Aldrich (St.
Louis, USA). b-glycerophosphate disodium salt was purchased from
Merck Millipore (Kilsyth, Australia). L-Ascorbic acid phosphate was
purchased from NovaChem Pty Ltd (Melbourne, Australia). Non-
essential amino acids (100X) and fetal bovine serum (FBS) were
purchased from Bovogen (Melbourne, Australia). Human oncosta-
tin-M (OSM) ELISA, anti-OSM and anti-gp130 blocking mono-
clonal antibodies and recombinant OSM, Wnt3A, GM-CSF, IL-4,
interferon-c (IFNc) and BMP-2 proteins were purchased from R&D
Systems (Minneapolis, USA). Ready-SET-GoH human TNF, IL-1b
and IL-10 ELISAs were obtained from eBioscience (San Diego, CA).
Ficoll-Paque was purchased from GE Healthcare Life Sciences
(Rydalmere, Australia). MethoCult GF H4534 (Iscove’s medium
containing 1% methylcellulose, 30% FBS, 1% bovine serum
albumin, 1024M 2-mercaptoethanol, 2 mM L-glutamine, 10 ng/
mL recombinant human GM-CSF, 10 ng/mL IL-3, and 50 ng/mL
stem cell factor) was purchased from Stem-Cell Technologies
(Tullamarine, Australia). Soluble RANKL158–316-GST fusion pro-
tein (RANKL) was produced in-house from a construct kindly
supplied by Dr. F. Patrick Ross (Hospital for Special Surgery, NY) as
previously described [24]. All other reagents were analytical grade.
Generation of macrophages and osteoclasts
Collection of human umbilical cord blood, isolation of a
mononuclear cell fraction, expansion of CFU-GM-derived oste-
oclast precursors and differentiation of mature human osteoclast
have been previously described [18]. Briefly, cord blood mono-
nuclear cell fraction (CBMC) was isolated by Ficoll-Paque density
gradient centrifugation and the cells (36106 cells/culture) were
suspended in 3.0 mL Methocult GF H4534 in 35 mm diameter (6-
well) plates and incubated at 37uC in humidified atmosphere of
5% CO2-air for 11 days to generate CFU-GM colonies (.80%)
and CFU-M colonies (5–10%); hereafter these CBMC-derived
populations are referred to as CFU-GM, as previously described
[19]. These cell populations were pooled in PBS, centrifuged, and
resuspended in DMEM containing 10% heat inactivated (55uC for
30 minutes) FBS, non-essential amino acids, penicillin 50 U/mL;
streptomycin 50 mg/mL and 2 mM L-glutamine (DMEM/FBS)
and then cultured (76106 cells/175 cm2 flask) for 14 days with M-
CSF (25 ng/mL) alone to generate proliferating macrophages, or
M-CSF and RANKL (125 ng/mL) to generate osteoclasts.
To generate classically activated macrophages [25] CFU-GM
(76106 cells/175 cm2 flask) were cultured in MEM/FBS with one
of the three following stimulations: (i) GM-CSF (10 ng/mL) for
20 days, (ii) GM-CSF (10 ng/mL) for 14 days, followed by GM-
CSF (10 ng/mL) and interferon-gamma (IFNc) (1?? ng/mL) for
6 days, or (iii) GM-CSF (10 ng/mL) for 14 days, followed by GM-
CSF (10 ng/mL) and IFNc (100 ng/mL) for 3 days, then GM-
CSF (10 ng/mL) and lipopolysaccharide (LPS; 100 ng/mL) for
3 days. To generate macrophages undergoing alternative activa-
tion, CFU-GM (76106 cells/175 cm2 flask) were cultured in
MEM/FBS with M-CSF (25 ng/mL) for 11 days, then M-CSF
(25 ng/mL) and IL-4 (100 ng/mL) for 6 days.
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Confirmation of macrophage and osteoclast identity
Adherent macrophages were identified by a-napthyl acetate
esterase (non-specific esterase; NSE) histochemistry. Cell were
fixed in 4% paraformaldehyde for 10 mins, then incubated in Fast
Blue BB-based substrate solution prepared from a commercial kit
as per manufacturer’s instructions (Sigma-Aldrich, Catalogue
number 91A-1KT). Cells were also scraped from the culture
surface and incubated with phycoerythrin labelled anti-CD14
(anti-CD14-PE) or anti-CD16-FITC (BD Australia, North Ryde,
Australia) antibodies and analysed by flow cytometry as below.
Figure 1. Generating and characterising CFU-GM and CFU-GM-derived populations. (A) Schematic of CM generation as outlined in
Materials and Methods: CFU-GM expanded from cord blood mononuclear cells (by incubation for 10 days in semi-solid medium and growth factors)
were used to generate osteoclast and macrophage populations. CM from these cells were then used to treat MSC in experiments. (B) CFU-GM and
macrophage populations (after CM collection) were analysed for CD45 expression by flow cytometry and these CD45+ cells examined for CD14 and
CD16 expression. (C) Representative photomicrographs of macrophage cultures showing phase contrast image (plastic substrate), nonspecific
esterase (NSE) histochemical staining (dentine substrate), TRAP histochemical staining (dentine substrate), and dentine substrate of macrophage
culture after the macrophages have been removed to reveal a complete lack of pit formation. (D) Photomicrographs of osteoclastic cultures, showing
phase contrast image (plastic substrate, red arrowhead indicating osteoclasts), TRAP histochemical staining (dentine substrate, including expanded
view with osteoclasts indicated by red arrowhead), and dentine substrate of osteoclast cultures after the osteoclasts were removed, which has been
stained to reveal extensive pit formation. All scale bars = 100 mm.
doi:10.1371/journal.pone.0073266.g001
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Osteoclasts were identified by tartrate-resistant acid phosphatase
(TRAP) expression and multinuclearity (.2 nuclei) [26]. To
confirm the formation of functional osteoclasts, CFU-GM were
seeded (46104/well) into 6 mm diameter tissue culture wells (96-
well tissue culture plates) containing 28.3 mm2 slices of sperm
whale dentine prepared as previously described [25] and cultured
in 200 mL DMEM/FBS plus M-CSF (25 ng/mL) and RANKL
(125 ng/mL) for 14 days, with medium and mediators replaced
twice weekly. After 14 days the cells were fixed in 1% formalin
and histochemically reacted to confirm TRAP expression, then
cells were removed from dentine slices by brief sonication in
chloroform:methanol 2:1. Xylene-free black ink was applied to the
resorbed surface of each slice and residual ink removed by wiping
the dentine surface against absorbent paper, leaving resorption pits
stained black for assessment by transmission light microscopy [18].
Conditioned medium collection
After 14 days culture in either M-CSF (25 ng/mL), or M-CSF
(25 ng/mL) and RANKL (125 ng/mL) to produce macrophages
and osteoclasts respectively, cells were cultured for a further 3 days
in DMEM/FBS with M-CSF (25 ng/mL) (Fig. 1A). This
macrophage (MW-CM) and osteoclast conditioned medium (OC-
CM) was filtered (0.22 mm pore size filters; Corning, Lowell, MA)
and stored at280uC until further use. For activated macrophages,
conditioned medium was collected from the last 3 days from each
of the stimulated culture conditions. Cell culture medium
containing the same mediators was also incubated in the absence
of cells for 3 days and this aged medium subsequently used as the
experimental control medium.
Isolation and culture of adipose tissue-derived MSC
Human adipose tissue was collected during elective surgery. To
isolate MSC, tissue was teased from blood vessels, minced with a
scalpel blade, and digested for 30–45 min with 0.075% collage-
nase at 37uC with gentle agitation. Enzyme activity was
Table 1. Characterisation of CFU-GM and CFU-GM-derived M-
CSF-dependent macrophages by flow cytometry.
CFU-GM Cells M-CSF Treated Cells
CD45+ 57.46.4260.17% 94.9460.38%
CD14+ 35.4260.39% 98.0360.33%
CD16+ 6.7760.61% 46.2861.06%
CD14+ /CD16+ 6.9260.51% 45.9560.39%
CD14+ /CD86+ 0% 81.8560.92%
CD206+ 31.9260.29% 71.8960.86%
CD14+ /CD206+ 28.8460.27% 72.8960.40%
CD34+ 3.7061.85% 1.9261.21%
CFU-GM cells taken immediately after their expansion in semi-solid medium
were fluorescently stained by primary labelled antibodies for CD45, CD14,
CD16, CD34, CD86 and CD206, and the proportion of positive cells estimated.
These cells were compared with macrophages generated from CFU-GM cells by
treatment with M-CSF (17 days); two independent experiments analysed in
triplicate, mean 6SEM shown.
doi:10.1371/journal.pone.0073266.t001
Figure 2. Characterisation of MSCs and their differentiation. (A) FACS analysis of expanded adipose stromal cells in culture revealed a high
proportion of cells expressing CD90, CD73 and CD105, indicating a population enriched in MSC; PE = phycoerythrin label, FITC = fluoroscein
isothiocyanate label. To assess their osteogenic capacity, cells were cultured in medium with or without osteogenic factors (OSG; ascorbate,
dexamethasone and b-glycerophosphate) for 7, 14 and 21 days and assessed (B) for ALP activity; (C) Photomicrograph ALP histochemical staining of
MSC cultures after 0 and 21 days of OSG stimulus, the latter showing clusters of strongly ALP positive (blue) cells; bars = 100 mm. (D) The ability of the
cells to form mineralised matrix was determined by Alizarin Red binding assay. Data displayed as mean6 SEM with statistical significance determined
by two-way ANOVA, General Linear Model, and Tukey’s post hoc test, n = 6, **p#0.01, ***p#0.001 relative to respective (no OSG) controls.
doi:10.1371/journal.pone.0073266.g002
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neutralised with basal medium (DMEM containing 10% FBS and
penicillin 50 U/mL; streptomycin 50 mg/mL) and the cells were
centrifuged at 12006g for 10 mins, resuspended and filtered
through a 100 mm cell strainer to remove remaining tissue debris.
Cells were pelleted by centrifugation and seeded (106 cells) in tissue
culture flasks in basal medium, then incubated at 37uC in
humidified atmosphere of 5% CO2-air. Cells were passaged by
treatment with 0.025% trypsin/EDTA in PBS and diluted 1:10 in
DMEM/FBS. MSC derived from individuals (unpooled) were
employed in assays after 5 passages.
Differentiation of MSC in medium containing osteogenic
(OSG) factors
MSC (104 cells/well) were seeded in 6 mm diameter culture
wells in DMEM/FBS and cultured overnight. For MSC differen-
tiation time-course, cells were then cultured in osteogenic medium
(DMEM/FBS containing dexamethasone (100 nM) b-glycero-
phosphate (10 mM) and ascorbate-2-phosphate (100 mM)) and
assessed for ALP activity and matrix mineralisation at 7, 14 and
21 days of incubation. For conditioned medium experiments,
MSC (104 cells/well) were seeded in 6 mm diameter culture wells
and cultured in 50% conditioned medium plus 50% osteogenic
medium; final concentrations in MSC cultures of dexamethasone
b-glycerophosphate and ascorbate-2-phosphate were thus 50 nM,
5 mM and 50 mM respectively. Cells were assessed for ALP
Figure 3. The effects of MW-CM and OC-CM on MSC mineralisation and metabolic activity. 104 MSC were cultured in 50% OC-CM or MW-
CM with osteogenic factors for 14 days. (A) Metabolic activity of cultures assessed by MTT assay. (B) Matrix mineralisation, assessed by quantification
of bound Alizarin Red, was greatly enhanced by OC-CM or MW-CM treatment of MSC cultured in osteogenic medium. (C) Representative
photomicrographs of stained cultures from B; scale bars = 100 mm. Data displayed as mean 6 SEM. Statistical significance relative to controls
(adjoining grey columns) determined by Two-Way ANOVA, GLM (A) and One-Way ANOVA, Tukey’s post hoc test (B), n = 6, *p#0.05, ***p#0.001
difference from control medium or as indicated with capped line. Control = 50% medium conditioned in the absence of cells.
doi:10.1371/journal.pone.0073266.g003
Figure 4. MW-CM and OC-CM stimulate MSC osteoblastic maturation. 104 MSC were cultured with 50% OC-CM, MW-CM or control medium
as noted with osteogenic factors for 14 days and osteoblastic differentiation characteristics (other than matrix mineralisation) were assessed. (A) ALP
activity in CM-treated MSC in the presence or absence of osteogenic factors (OSG; ascorbate and dexamethasone); n = 6. Effects of 14 days of MW-CM
treatment (with OSG), on MSC mRNA levels of (B) Runx2 (C) OSX (D) PTH1R, determined by real-time RT-PCR. Data displayed as mean 6 SEM.
Statistical significance determined by t-test (B,C,D) or One-Way ANOVA (Tukey’s post hoc test), (A, *p#0.05, **p#0.01, ***p#0.001 difference from
untreated controls or as indicated with capped line; n = 3 or as indicated. Control = 50% medium conditioned in the absence of cells.
doi:10.1371/journal.pone.0073266.g004
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activity at 4 days and matrix mineralisation at 14 days or as
indicated. For antibody neutralisation assays, MSC were cultured
in 50% conditioned medium plus osteogenic medium containing
(final concentration) 1 mg/mL anti-gp130 or 10 mg/mL anti-OSM
monoclonal antibodies or mouse IgG1 control, then assessed for
ALP at 4 days and matrix mineralisation and metabolic activity by
MTT assay at 14 days.
MTT metabolic activity assay
After culture, media was completely removed from appropriate
wells and MTT solution containing 1.2 mM 3-(4,5-Dimethylthia-
zol-2-yl)-2,5-diphenyltetrazolium bromide in DMEM was added,
and then incubated for 37uC for 4 hours. The supernatant was
completely removed and the cells containing the formazan
product were solubilised in DMSO for 30 mins. The solubilised
solution was transferred to a fresh 96-well plate and optical density
(OD) measured at 570 nm using a Tecan Genios Pro photo-
spectrometer.
Alkaline Phosphatase (ALP) activity assay
To determine cellular ALP activity, cells were lysed in 0.1%
Triton X-100 for 30 m at room temperature. A pre-warmed
solution containing 10 mg/mL p-nitrophenylphosphate (pNPP) in
10% v/v diethanolamine buffer; 0.5 mM MgCl2 pH 9.8 was then
added to the lysates and optical density of samples were assessed
using a Tecan Genios Pro photospectrometer, OD measured at
410 nm at 37C. This was measured at 2.5 min intervals for
30 mins. Results were converted to standard international units
(SIU), equivalent to the conversion by ALP of 1 mM of pNPP to
p-nitrophenyl (pNP) per minute. A standard curve was generated
by serially diluting 1 mM pNP in diethanolamine buffer and data
presented as relative SIU.
Figure 5. The effects of MW-CM and OC-CM on osteoblastic maturation of MSC are gp130 and OSM dependent. MSC were cultured in
either 50% MW-CM (A-C, F,G) or OC-CM (D, E, H) in osteogenic media in the presence of anti-gp130 (1 mg/mL) or anti-OSM (10 mg/mL) antibodies or
IgG (10 mg/ml; control) as indicated. MSC were cultured for 4 days and assessed for ALP activity (A-E), or cultured for 10 days and mineralisation
assessed by Alizarin Red binding assay (F-H). Data displayed as mean6 SEM; statistical significance determined by one-way ANOVA (Tukey’s post hoc
test), all data n = 4; *p#0.05 **p#0.01, ***p#0.001 relative to controls (grey columns) or as indicated by capped lines.
doi:10.1371/journal.pone.0073266.g005
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Quantification of in vitro matrix mineralisation
MSC were fixed in 1% formalin for 30 minutes and then
treated with 40 mM Alizarin Red (ALZ) for 15 min at RT. For
quantification of staining, a protocol was adapted from that
described by Stanford et al. [27]. Cells were washed repeatedly
with distilled water and the stain was then solubilised in 3%
cetylpyridinium chloride (CPC) in 20 mM sodium phosphate
buffer for 45 min. The solubilised supernatant was transferred to a
new 6 mm diameter wells and OD measured at 570 nm using a
Tecan Genios Pro photospectrometer. A standard curve was
generated for ALZ by serially diluting 1 mM ALZ in 3% CPC.
OD readings were converted to CaCl2 mg/well. CaCl2 per well is
based on molar equivalent of ALZ to Ca (1:1); 1 mM (mmol/L) is
equivalent to 22.196 ng/L CaCl2
Flow cytometric analysis
Flow cytometry analyses of adipose tissue derived cells, CFU-
GM and CFU-GM-derived cells were performed using FacsCa-
libur and CELLquest software (Becton Dickinson, NJ). Approx-
imately 16105 cells from each population were labelled with
appropriate phycoerythrin (PE), fluoroscein isothyocyanate (FITC)
and peridinin-chlorophyll protein (PerCP) labelled antibodies
including anti-CD45-FITC, anti-CD14-PE, anti-CD16-FITC,
anti-CD34-PE, anti-CD-34–PerCP, anti-CD86-PercP, anti-
CD206-FITC, anti-CD73-PE, anti-CD90-FITC (BD Australia,
North Ryde, Australia) and anti-CD105-FITC (Abcam plc,
Cambridge, UK) according to manufacturer instructions. As
negative controls for the fluorescent cell labelling we employed
appropriate isotype controls for the antibodies employed. includ-
ing anti-IgG-FITC, anti-IgG-PE, anti-IgG-PerCP (BD Australia)
or anti-IgG2a-FITC (Abcam).
Real time RT-PCR and semiquantitative RT-PCR analysis
of mRNA expression
Cellular RNA was isolated by lysing cells in Trizol and using the
illustra RNAspin Mini Kit (GE Healthcare, Melbourne Australia).
RNA concentration was determined by spectrophotometer
(Nanodrop ND1000). cDNA was synthesized from RNA using
the SuperscriptH III First Strand Synthesis SuperMix system (Life
Technologies) as per manufacturer’s instructions. To quantify the
expression of human Runx2, osterix and OSM mRNA levels we
employed real-time PCR analysis of cDNA performed in a 7500
Fast Real-Time PCR System (Applied Biosystems), using Taq-
ManH Gene Expression Assays using standard commercially
available primer/probe mixtures (Applied Biosystems catalogue
Hs00231692_m1, Hs01866874_s1 and Hs00171165_m1 respec-
tively). Relative gene expression units were determined using the
formula 22DCt61000, where DCt values represent the difference
between the Ct of the gene of interest and b-actin. For analysis of
IL-6, TNF and the classical parathyroid hormone (PTH) receptor
(PTH1R) mRNA expression real time PCR analysis (Stratagene
Mx3000P) of cDNA was performed using PlatinumH SYBRH
Green qPCR supermix UDG (Invitrogen) according to manufac-
turer’s instructions and the following conditions: 1 cycle 10 mins
95uC; 40 cycles 30 seconds at 95uC, 1 min at 60uC, 30 seconds at
72uC; 1 cycle 1 min at 95uC, 30 seconds at 55uC, 0 seconds at
95uC) normalized to hypoxanthine phosphoribosyltransferase
(HPRT). Primer oligo nucleotide sequences used for real time
RT-PCR using the SYBRH Green qPCR-based method were as
follows:
HPRT (GenBank accession NM_000194.2) 59-GACCAGT-
CAACAGGGGACAT-39, reverse 59-CGACCTTGACCATGT-
TTGGA-39;
Human TNF (GenBank accession NM_000594.3) forward 59-
ATCTTCTCGAACCCCGAGTGA-39, reverse 59- CGGTTCA-
GCCACTGGAGC T-39;
Human IL-6 (GenBank NM_000600.3) forward 59- AAAT-
TCGGTACATCCTCGACGG-39, reverse 59- GGAAGGTTCA-
GGTTGTTTTCTGC-39;
Human PTH1R (GenBank accession NM_000316.2) forward
59- ACCTGCACAGCCTCATCTTCA-39, reverse 59- CACA-
CAGCCACGAAGACAGC-39.
To assess human BSP mRNA expression we employed semi-
quantitative RT-PCR analysis. cDNA was prepared as above and
PCR reactions employed KAPA2G Robust Hotstart PCR kits
(KAPA Biosystems, Woburn, MA) according to manufacturer’s
instructions using an Applied Biosystems Veriti thermal cycler
machine (Life Technologies, Carlsbad, CA). Glyceraldehyde-3
phosphate dehydrogenase (GAPDH) mRNA was used as a
housekeeping gene expression reference. For BSP the following
conditions were used: after 10 mins at 95uC, we used 32 thermal
cycles (30 seconds at 95uC, 30 seconds at 58uC, 60 seconds at
72uC) followed finally by 10 min at 72uC. GAPDH analysis used
similar conditions with 30 thermal cycles. PCR generated products
were separated by electrophoresis on a 1.5% agarose gel
containing Sybr SafeH DNA stain (Invitrogen) then visualised
Figure 6. OSM production by macrophages, osteoclasts and MSCs. (A) Levels of OSM protein in MW-CM and OC-CM assessed by ELISA. (B)
Relative OSM gene expression in macrophage and OC cultures assessed by RT-PCR. (C) Lack of OSM mRNA detection in CM-treated (4 days) MSC
cultures; ‘Pos. Cont’ shows macrophage mRNA data as a method positive control. Data displayed as mean 6 SEM and statistical significance relative
to controls (or as indicated by capped bars) determined by one-way ANOVA (Tukey’s post hoc test) or Student’s t-test, n = 4, *p#0.05, ***p#0.001 or
as indicated by capped lines.
doi:10.1371/journal.pone.0073266.g006
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under ultraviolet light using a Biorad (Gladesville, Australia) Gel
DocTM 2000 imaging system. Primer oligo nucleotide sequences
used for semi-quantitative RT-PCR were as follows:
BSP (GenBank accession NM_004967.3; IBSP) forward 59-
CCTTCTCTGCCCTCTCACTCC-39, and reverse 59- AT-
GAGTCACTACTGCCCTGAAC-39, product size of 205 base
pairs;GAPDH (GenBank accession NM_001256799.1) forward 59-
CACTGACACGTTGGCAGTGG -39 and reverse 59- CATG-
GAGAAGGCTGGGGCTC -39, product size 405 base pairs.
Measurement of BMP and canonical Wnt activity
To detect BMP and Wnt activity in conditioned medium we
employed luciferase reporter transfection assays. BMP-response
element (BMP-RE) [28] and TOPflash TCF/LEF (with a b-
catenin-sensitive promoter to detect canonical Wnt signals)
Upstate Biotechnology, NY) reporter construct DNA (0.1 mg/
well) was co-transfected with pRL Renilla luciferase construct
(0.1 mg/well; Promega), into UMR106.01 osteoblast-like cells [29]
with FugeneH 6 transfection reagent (Promega) according to
manufacturer instructions. Cell cultures were treated in triplicate
Figure 7. The effects of OSM on osteoblastic maturation of MSC. To confirm OSM actions, MSC were cultured in osteogenic media with
recombinant OSM (10 ng/mL) for 4 days and assessed for (A) ALP activity, or for 10 days and assessed for (B) mineralisation, by Alizarin Red binding
assays; blocking of recombinant OSM actions by antibodies to gp130 and OSM was confirmed; n = 4. (C) OSM dose response of MSC ALP levels (at day
4) and (E) photomicrographs ALP histochemical stain in control and OSM treated MSC, day 4; bars = 100 mm. (E) BMP-2 dose response of MSC ALP
levels, day 4. (F) Synergistic actions of OSM with BMP-2 but not Wnt3A co-treatment on MSC ALP levels at 4 days of incubation (with osteogenic
factors). Data displayed as mean 6 SEM and statistical significance relative to controls (grey columns), or as indicated by capped bars, determined by
one-way ANOVA (Tukey’s post hoc test), n = 3 unless noted, *p#0.05 **p#0.01, ***p#0.001.
doi:10.1371/journal.pone.0073266.g007
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Figure 8. The influence of IL-4 on CFU-GM-derived macrophage stimulation of MSC osteoblastic differentiation. CM was generated
from macrophages cultured in M-CSF (25 ng/mL) or M-CSF plus IL-4 (100 ng/mL) for 14 days, and medium conditioned in these cells for a further
3 days. (A) IL-10 levels in CM determined by ELISA; ‘Control’ = medium (with M-CSF) conditioned without cells. (B) MSC were exposed to CM for
4 days and assessed for ALP activity or (C) exposed to CM for 14 days and mineralisation assessed by staining by Alizarin Red binding assays. (D)
Levels of OSM in CM assessed by ELISA. Data displayed as mean6 SEM; statistical significance determined by one-way ANOVA (Tukey’s post hoc test),
n = 4, **p#0.01, ***p#0.001 compared to controls (grey columns) or as indicated (capped line).
doi:10.1371/journal.pone.0073266.g008
Figure 9. The effects of classical activation on the ability of macrophages to stimulate osteoblastic commitment of MSC. CFU-GM
populations were cultured in GM-CSF (10 ng/mL) for 14 days, then stimulated with the following: GM-CSF (‘GM’) alone; GM-CSF plus IFNc
(‘‘GM+IFNc’’); or GM-CSF plus IFNc followed by 3 days in GM-CSF plus LPS (‘‘GM+IFNc+LPS’’). (A) Higher IL-6 and TNF mRNA expression in
macrophages generated in GM-CSF than M-CSF (determined by RT-PCR). (B) TNF protein was determined (by ELISA) in conditioned medium from M-
CSF, GM, GM+IFNc and GM+IFNc+LPS treated macrophages. ‘Cont.’ = medium (containing GM-CSF) conditioned without cells. (C) MSC were
exposed to CM from the cells indicated and MSC cultures assessed for ALP activity after 4 days and (D) mineralisation (Alizarin Red binding assay) at
14 days. (E) Levels of OSM in CM assessed by ELISA. Data displayed as mean 6SEM; statistical significance determined by one-way ANOVA (Tukey’s
post hoc test); A,B n = 3, C-E n = 4. *p#0.05, **p#0.01, ***p#0.001 compared to their controls (in adjoining grey columns) or as indicated by capped
lines.
doi:10.1371/journal.pone.0073266.g009
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with CM for 24h, PBS rinsed then lysed wth Passive Lysis Buffer
(Promega) for 24h at 4uC. Lysates were transferred to a white flat
bottomed 96 well microplate (Corning, Lowell, MA) and signal
measured using firefly Luciferase substrate and Stop and GloH
reagents (Promega) as per manufacturer instructions using a
EnVision multilabel (PerkinElmer, Waltham, MA) plate reader.
Statistical analyses
Data are expressed as the mean 6 SEM where applicable.
Differences between groups were determined using either
Student’s t-test (for 2 way comparison), or by one-way ANOVA
or two-way ANOVA (GLM), followed by Tukey’s post hoc test as
indicated. Statistical significance is indicated thus: * p,0.05, **
p,0.01, *** p,0.001. Statistical significance indicated on graphs
is relative to control cultures or between groups connected with
capped line.
Results
Characterisation of cell populations
Macrophages: Flow cytometric analysis showed that most M-CSF
expanded CFU-GM cells expressed high levels of leukocyte
common antigen (CD45) and 98% expressed CD14 (Fig. 1B,
Table 1), confirming them as macrophages. A large proportion of
these cells were also CD14+/CD16+ (Table 1), resembling the
‘non-classical’ subpopulation of monocytes [30,31]. A majority of
these macrophages (81% and 72% respectively) expressed antigen
presentation co-stimulatory molecule CD86 and mannose receptor
CD206 (Table 1). Populations of macrophages generated by
treating cord blood-derived CFU-GM with M-CSF for 14 days
expressed NSE but little or no TRAP activity, and did not resorb
dentine substrate (Fig. 1C). Conditioned medium from these
macrophages showed no detectable human IL-1b and TNF
(ELISA, data not shown), while IL-10 levels were detectable but
generally low (83.2612.2pg/ml, mean6SEM).
Osteoclasts: Multinucleated osteoclasts were generated by treating
CFU-GM with M-CSF and RANKL for 14 days. All cells in these
cultures expressed TRAP, and produced extensive resorption pits,
demonstrating their functional osteoclastic status (Fig. 1D).
MSC: MSC populations were isolated from adipose tissue for
long term culture. Flow cytometric analysis indicated that MSC
populations passaged .5 times contained .95% of cells that were
CD73+, CD90+ and CD105+ (Fig. 2A). CD45+ cells were not
detected, indicating that leukocytes were not present. Cells were
seeded 104 cells/6 mm diameter culture well for long term culture.
The OB-forming potential of MSC (after 5 passages) was
confirmed by culture in osteogenic medium; these cells expressed
little ALP by day 14, but expressed high levels by day 21
(Fig. 2B,C). MSC cultures in osteogenic medium formed only low
levels of mineralised matrix by day 14 but very high levels by day
21 (Fig. 2D). MSC formed large numbers of adipocytes stained by
Oil Red O when incubated with a standard adipogenic stimulus
(1 mM dexamethasone plus 175 nM insulin, 450 mM IBMX and
100 mM indomethacin) for 14 days (data not shown), confirming
the multipotential nature of these MSC populations.
Effects of macrophage- and osteoclast-conditioned
media on osteoblastic differentiation of MSC
Cell metabolism levels in MSC cultures were raised by the
presence of osteogenic medium but were otherwise unaffected by
addition of 50% MW-CM or OC-CM in cultures (Fig. 3A),
suggesting such CM has little or no overall effect on cell growth or
activity (Fig. 2D). Nevertheless, after 14 days incubation (in the
presence of base osteogenic medium) the presence of either MW-
CM or OC-CM addition greatly increased the levels of
mineralization in the MSC, by five-fold and three-fold respectively
(Fig. 3B,C, Fig. S1). In such cultures ALP levels were also strongly
elevated (Fig. 4A), consistent with enhanced osteoblastic differen-
tiation. In contrast, conditioned medium from M-CSF-starved
macrophages did not induce mineralisation in MSC (data not
shown). Surprisingly, we noted that the presence of osteogenic
medium (i.e., medium containing ascorbate, dexamethasone and
b-glycerophosphate) was not necessary for the pro-osteoblastic
actions of MW-CM and OC-CM. Omission of osteogenic
components from the culture medium resulted in lower levels of
MSC ALP levels after 14 days, but ALP levels were still greatly
enhanced by the conditioned media (Fig. 4A); indeed the responses
to CM were similar to those of cultures in osteogenic medium in
terms of fold change relative to baseline. Thus, pro-osteoblastic
actions of these conditioned media were not dependent on
osteogenic supplements and may arise through a different
mechanism. Since MW-CM was able to elicit the highest levels
of osteoblastic differentiation in MSC we investigated how quickly
this occurred compared to conventional 14-day osteogenic
treatment. As high ALP levels were induced within 4 days
(Fig. S1) this culture period was employed in the ALP analyses
below.
To further characterise the effects of MW secreted factors on
MSC osteoblastic commitment we investigated the expression of
Runx2 and osterix (transcription factors critical for osteoblastic
commitment and differentiation), as well as the classical PTH
receptor (PTH1R) and bone sialoprotein (BSP) which are
characteristically expressed by mature osteoblasts. Indeed, MW-
CM treatment of MSC caused mRNA levels these four factors to
rise significantly (Fig. 4B,C,D and Fig. S1C), consistent with
enhanced osteoblastic maturation.
Osteoblastic stimuli produced by CFU-GM-derived
macrophages and osteoclasts act in a gp130- and OSM-
dependent manner
We investigated the involvement of gp130-dependent cytokines
on the pro-osteoblastic effects of MW-CM and OC-CM using anti-
gp130 and anti-OSM monoclonal antibodies. Increased ALP
levels induced by MW-CM treatment of MSC cultures for 4 days
was abolished by anti-gp130 antibody (1 mg/mL) but unaffected
by control IgG1 (Fig. 5A,B). Anti-OSM (10 mg/mL) also
completely abolished the MW-CM-elicited rise in ALP (Fig. 5C).
Increases in ALP elicited by OC-CM treatment were similarly
abolished by anti-gp130 and anti-OSM antibodies (Fig. 5D, E).
Consistent with these observations, induction of matrix mineral-
isation by MW-CM and OC-CM treatment of MSC over 14 days
was also blocked by anti-gp130 and by anti-OSM antibodies
(Fig. 5F, G, H) further confirming that this phenomena are OSM-
dependent.
Production of OSM by CFU-GM-derived macrophages
and osteoclasts, and by MSC
Having shown that the effects of MW-CM and OC-CM were
OSM dependent, we determined by ELISA methods that OSM
was indeed detectable in MW-CM and in OC-CM (Fig. 6A); RT-
PCR analysis also confirmed that our macrophage and osteoclast
populations expressed OSM mRNA (Fig. 6B) although the
presence of M-CSF itself did not have a large effect on OSM
mRNA levels.
In our differentiating MSC cultures, the added conditioned
medium is not the only possible source of OSM, since the MSC
themselves may produce it, indeed, MW-CM may contain factors
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that induce OSM production in MSC cultures. However, by RT-
PCR methods OSMmRNA was undetectable in the MSC and did
not become evident with MW-CM treatment (Fig. 6C). Further to
this, medium taken from MSC cultures after 4 days of incubation
contained very low (indeed, barely detectable) levels of OSM
protein as did medium from MSC exposed to MW-CM for this
period (Fig. S2A). These observations suggest autocrine actions of
MSC-derived OSM are unlikely to contribute to osteoblastic
differentiation responses in MW-CM-stimulated MSC cultures.
The effects of recombinant OSM on MSC cultures, and
OSM interactions with osteogenic factors BMP-2 and
Wnt3A
Since OSM activity is essential for the osteoblastic actions of
MW-CM and OC-CM on our human adipose tissue MSC, we
confirmed that, as previously described, [32] 10 ng/mL recom-
binant human OSM strongly induces ALP and mineralisation in
MSC cultures (Fig. 7A,B). However, our ELISA data in Fig. 6
indicated that the OSM levels in MW-CM and OC-CM were very
low, around 0.1 ng/ml. We thus tested the effects of recombinant
OSM levels in this range on MSC ALP levels. We found that
0.1 ng/ml recombinant OSM was indeed sufficiently potent to
greatly increase these ALP levels, with an almost 5-fold increase
(observed over 4 days) and higher ALP levels with greater OSM
concentrations (Fig. 7C,D); matrix mineralisation was also
significantly increased by 0.2 ng/ml OSM (Fig. S2B). Since
OSM is likely to be found in microenvironments where other
osteogenic factors are present we examined the interaction of low
concentrations of OSM with BMP-2 and Wnt3A on MSC
cultures; note that we did not find significant BMP or Wnt
activity in MW-CM itself using luciferase reporter assays
(Fig. S2C,D). BMP-2 100 ng/ml significantly induced our adipose
tissue MSC ALP levels (4 day cultures; Fig. 7E), though much less
potently than OSM; Wnt3A treatment had no detectable effects
(Fig. S2E). Co-treatment with 50 ng/ml BMP-2 and 0.025 ng/ml
OSM (both concentrations without significant effects on MSC)
caused a sizable increase in ALP levels, suggesting synergistic
interactions between these two factors (Fig. 7F). The effects of
2 ng/ml OSM also showed significant enhancement by 50 ng/ml
and 100 ng/ml BMP-2 (Fig. S2F). Recombinant Wnt3A did not
detectably influence OSM actions on MSC (Fig. 7F).
The effects of activation on CFU-GM-derived
macrophage pro-osteoblastic stimulation of MSC
To investigate the influence of macrophage activation we first
investigated the effect of alternative activation of macrophages
using IL-4 (10 ng/mL) treatment applied for 3 days. IL-4
treatment of the macrophages for 3 days did not elicit TNF or
IL-1b levels but, consistent with alternative activation, significantly
increased levels of human IL-10 produced (Fig. 8A). IL-4
treatment of macrophages did not significantly affect the ability
of CM generated from these cells to enhance MSC ALP
expression and matrix mineralization (Fig. 8B,C). OSM levels in
CM generated from IL-4-treated cells were slightly greater than
positive controls (Fig. 8D), although we could not detect any
difference in OSM mRNA expression between M-CSF- and M-
CSF+IL-4-treated macrophages (data not shown).
To investigate the effects of classical activation, CFU-GM-
derived cells were expanded with GM-CSF 10 ng/mL (rather
than M-CSF) for 14 days (GM-MW); some GM-CSF expanded
cells were also further activated by treatment with IFNc (1 ng/
mL) or a combination of IFNc plus 100 ng/mL LPS (Fig. 9). Both
GM-CSF and M-CSF expansion produced cell cultures of similar
cell density after 14 days. GM-CSF-expanded cells (GM-MW)
expressed higher levels of IL-6 mRNA than M-CSF expanded cells
(Fig. 9A). IL-1b, IL-10 or TNF were not detectable in conditioned
medium of these cells but activation by IFNc or IFNc plus LPS
significantly induced TNF production (Fig. 9B). These IFNc plus
LPS-activated cell populations analysed by FACS had far fewer
CD16+ cells (1.0160.99%) than M-CSF-expanded macrophage
populations (Table 1); the IFNc plus LPS-activated cell contained
no CD14+/CD16+ and very few CD14+/CD206+ cells
(2.060.90%), while CD14+/CD86+ were numerous
(26.2960.89% of cells).
The CM from these activated macrophage-containing popula-
tions (GM-MW, GM+ IFNc-MW and GM+ IFNc+LPS-MW) all
failed to increase MSC ALP and mineralisation levels in MSC
relative to negative controls (Fig. 9C,D). OSM levels in medium
conditioned by these activated macrophage populations were also
lower than medium conditioned by M-CSF-treated macrophages
(MW-CM; Fig. 9E).
Discussion
One of the most significant puzzles in bone biology is how
osteoblast formation and activity is controlled in normal healthy
bone and in disease states. The need for improved anabolic
therapies for bone makes identifying the mechanisms that underlie
osteoblast recruitment an important goal. Currently the main
bone anabolic therapy that is employed clinically is injected PTH.
This treatment stimulates bone formation through several
mechanisms, including enhancement of osteoblast survival and
reduction of sclerostin production by osteocytes [12]. However,
PTH anabolic action can be blunted by anti-resorptive drugs that
reduce osteoclast number [12,33]. This, and the coupling of
resorption and formation in bone remodelling suggest that
osteoclasts stimulate osteoblast action, although how this may
occur is not understood. We have presented here evidence
suggesting that human osteoclastic cells stimulate osteoblastic
differentiation of MSC. However, this capacity was shared by
macrophage populations from which our osteoclasts were derived,
showing that it is not osteoclast specific. Nevertheless, our work
(and that of Guihard et al [22]) suggest that not all types of
macrophages have this action and those with a close ontogenic
relationship with osteoclasts may be particularly pro-osteoblastic.
We found that this activity was not due to production of bone
morphogenetic protein (BMP) or Wnt activity (two well char-
acterised factors that drive osteoblast differentiation), but depend-
ed entirely on macrophage or osteoclast production of OSM, an
IL-6 cytokine family member.
OSM is an anabolic factor for bone in vivo that, in addition to its
effects on MSC [32], suppresses osteocytes production of
sclerostin, [34], a Wnt-inhibiting factor that is under active study
as a therapeutic target. We previously found that OSM has strong
bone anabolic effects in mice in vivo, but OSM can be produced by
a number of local cell types, including mature osteoblasts
themselves [34,35] and it is unclear to what degree OSM directly
causes murine MSC maturation. While an OSM-dependent
action of osteoclasts and macrophages may be significant for
MSC recruitment it is unlikely to explain how bone formation is
stimulated by osteoclast-initiated remodelling unless other factors
either direct MSC to the site of osteoclast activity or provide an
amplifying co-stimulus for OSM action. In this regard it is also
notable that mice deficient in the OSM receptor do not have
disordered bone formation [34]; OSM null mice have been also
been studied, particularly for haematopoiesis defects [36] but no
gross bone abnormality reported. We previously found that mice
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lacking gp130-SHP2/ERK signalling (but not gp130-STAT3
signals) do have reduced bone mass but not disordered remod-
elling [37]. Clearly, OSM cannot therefore be essential for normal
murine bone remodelling, although its actions are likely to overlap
with other related cytokines [38] and interact with other
osteogenic factors, as we found with BMP-2. These considerations,
and the fact that the degree of MSC recruitment in normal bone
modelling and remodelling is unclear, currently makes it difficult
to assess the importance of OSM in bone metabolism.
Our data is clearly consistent with an influence of macrophages
on MSC, but the nature of macrophage influence on bone
formation remains controversial. Striking observations were made
by Alexander et al. [16] in a fracture model where they noted that
depletion of c-fms+ cells (principally macrophages, but also
osteoclasts) greatly reduced osteoblast numbers and bone forma-
tion. Due to the location of resident macrophages near the bone
surface and the effects of macrophage depletion they proposed a
central role for macrophages in enhancing or maintaining bone
formation, involving osteal macrophages in close contact with
osteoblasts [14]. Given the many varied functions of macrophages
and the abundance of macrophages in bone and bone marrow,
this is certainly plausible. It also suggests that factors that stimulate
or recruit macrophages could indirectly influence bone formation,
and a role here for OSM is possible. Furthermore, we noted that
not only was OSM extremely potent in its effects on MSC but it
acted synergistically with BMP-2. The possibility that OSM
cooperates with this and other factors to increase bone formation,
in addition to the ability of OSM to suppress sclerostin and induce
production of osteoblastic factors like IL-33 [39], suggest that
further scrutiny of macrophage (and OSM) actions in bone are
warranted.
The work of Guihard et al. [22] and more recently Nicolaidou
et al. [23] identified that MSC (derived from human bone marrow
stroma) also undergo enhanced osteoblastic differentiation in
response to mature macrophages derived from human CD14+
circulating monocytes; this occurred in a manner at least partly
dependent on OSM. The conclusions of these studies otherwise
differ markedly in many respects, and differ in some respects to
our study. Guihard et al. [22] found that conditioned medium
from GM-CSF- and IFNc-stimulated monocyte-derived CD14+
cells (classically activated macrophages) drive osteoblastic differ-
entiation of MSC, and that this is enhanced by LPS treatment,
while conditioned medium from CD14+ monocytes treated with
alternative activators IL-4 or IL-10 did not. In contrast,
Nicolaidou et al. [23] found that medium conditioned by human
monocytes did not drive MSC osteoblastic differentiation at all
unless co-cultured with the MSC; consistent with this, conditioned
medium from monocyte/MSC co-cultures stimulated osteoblast
maturation in other MSC cultures. In our work we employed
proliferating macrophages derived from progenitors that resemble
immature bone marrow macrophages rather more than adult
monocytes; our M-CSF-treated cord blood-derived macrophages
expressed CD14 but also CD16, suggesting a ‘non classical’
monocyte phenotype [30]. Classical activation of these cells (which
reduced CD16 expression) resulted in lower OSM levels, also
indicating that these macrophages differ markedly from adult
monocytes employed by Guihard et al. We found that cord blood-
derived macrophages directly co-cultured with MSC induced only
a weak action on ALP expression compared to MW-CM (data not
shown). We are uncertain why this is the case, but it may be due to
technical aspects that require further study, as these immature
macrophages did not appear to thrive in such co-cultures. Our
studies also indicated that macrophages treated with either M-CSF
or M-CSF plus IL-4 produced strong (OSM-dependent) osteo-
blastic stimuli. This indicates that alternative macrophage
activation maintained their pro-osteoblastic activity, again unlike
the CD14+ adult monocyte derived populations studied by
Guihard et al. [22]. In general, these data collectively suggest
there may be significant differences between our CFU-GM-
derived macrophages and monocyte-derived macrophages. It
seems reasonable to assume that a pro-osteoblastic or anti-
osteoblastic outcome of a given stimulus could depend greatly on
features of the macrophage populations. This suggests that
determining the profile of macrophages present in bone and bone
lesions (which would presumably include both monoctyes and
CFU-GM) is critical for understanding the outcome of a particular
stimulus. A detailed comparison of our experimental system with
that used by Guihard et al. [22] and Nicolaidou et al [23] may also
clarify how macrophages affect bone formation. It is notable that
classically activated macrophages in vivo are associated with
chronic inflammation and low bone formation, and since
inflammation commonly drives osteolysis this can make inflam-
matory lesions very destructive to bone. However, inflammation
can have a pro-osteoblastic outcome, as commonly observed in
ankylosing spondylitis. The reasons for this are unclear but
properties of the recruited macrophages in these lesions could play
an influential role. Such contrasting effects on local bone
metabolism can also be seen in cancer invasion – for example,
although breast cancers are typically osteolytic, osteoblastic lesions
also occur.
In summary, we have found that macrophage- and osteoclast-
derived OSM stimulates MSC differentiation to osteoblasts. This
stimulation occurs more rapidly (within 4 days of incubation), than
widely used ascorbate/dexamethasone treatment, making this a
very useful experimental system. This OSM-mediated interaction,
consistent with the observations of Song et al. [32], may play a
significant role in stimulating and maintaining osteoblastic activity
in bone, at least where this dependent on MSC differentiation. We
found that immature M-CSF-dependent macrophages (which are
abundant in bone marrow), including those exposed to IL-4 to
induce alternative activation, are a good source of this pro-
osteoblastic activity. However this activity is significantly reduced
or abolished by GM-CSF exposure or classical activation,
although whether this is solely due to their reduced OSM
production or whether they produce anti-osteoblastic factors is
unclear. This work confirms that macrophages and osteoclasts can
have a major effect on osteoblastic cell recruitment from MSC,
although the specific phenotype of the macrophages present is
clearly important.
Supporting Information
Figure S1 Time course of MW-CM effects on MSC
maturation. MSC were cultured in medium containing
osteogenic factors (ascorbate, dexamethasone and b–glycerophos-
phate) for 4, 7 and 14 days, with or without addition of 50% MW-
CM as indicated, then assessed for (A) ALP activity and (B)
mineralisation. Data displayed as mean 6 SEM; statistical
significance determined by one-way ANOVA (Tukey’s post hoc
test), n = 4, **p#0.01 and ***p#0.001 compared to respective
control cultures. (C) BSP and GAPDH mRNA levels were
examined (by semi-quantitative RT-PCR) in MSC cultured for
14 days with osteogenic factors alone (Control) or with addition of
50% MW-CM; representative of 3 independent cultures.
(PDF)
Figure S2 The lack of production of OSM by MSC, BMP
and Wnt activity in MW-CM, and the influence of BMP-2,
Wnt3A and OSM on MSC maturation. (A) MSC were
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cultured in 50% MW-CM or control medium (‘Cont-Med’)
for 4 days. OSM levels in the resulting MSC-exposed culture
medium were assessed by ELISA but showed only very low
levels, much lower than MW-CM (‘Pos. Cont.’) alone. (B)
Detailed dose response of MSC matrix mineralisation (at day 7)
to OSM treatment. To detect BMP and Wnt protein activity
in MW-CM (50%), luciferase reporter-based assays were em-
ployed, using BMP-RE and TOPFlash reporters respectively. (C)
UMR106.01 osteoblastic cells transiently co-transfected with
BMP-RE luciferase and Renilla reporter constructs, 24h incuba-
tion; ‘Cont.’ = control medium conditioned without cells, BMP-2
= 100 ng/mL. (D) UMR106.01 cells were used as in B, but with
TOPflash luciferase constructs and Renilla reporter construct;
Wnt3A =100 ng/mL. (E) Lack of effects on ALP responses of
Wnt3A (100 ng/mL) after 4 days of incubation. (F) Co-operative
actions of 2 ng/ml OSM with BMP-2 (but not Wnt3A) co-
treatment on MSC ALP levels at 4 days of incubation with
osteogenic factors; n = 3. Data displayed as mean 6 SEM;
statistical significance determined by one-way ANOVA (Tukey’s
post hoc test), all n = 3. *p#0.05, **p#0.01 and ***p#0.001
compared to control cultures (grey columns).
(PDF)
Acknowledgments
The authors would like to thank Drs Nicole Horwood and Vicky
Nicolaidou (Kennedy Institute of Rheumatology, University of Oxford,
United Kingdom) for helpful advice and discussion of this work.
Author Contributions
Conceived and designed the experiments: TJF PRE GCN JMWQ.
Performed the experiments: TJF JMH PPS DE FMC JMWQ. Analyzed
the data: TJF JMH PPS JMWQ. Contributed reagents/materials/analysis
tools: TJF JMH PRE IH JMWQ. Wrote the paper: TJF GCN JMWQ.
References
1. Long F (2012) Building strong bones: molecular regulation of the osteoblast
lineage. Nat Rev Mol Cell Biol 13: 27–38.
2. Lee RH, Kim B, Choi I, Kim H, Choi HS, et al. (2004) Characterization and
expression analysis of mesenchymal stem cells from human bone marrow and
adipose tissue. Cell Physiol Biochem 14: 311–324.
3. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, et al. (2006)
Minimal criteria for defining multipotent mesenchymal stromal cells. The
International Society for Cellular Therapy position statement. Cytotherapy 8:
315–317.
4. Kern S, Eichler H, Stoeve J, Kluter H, Bieback K (2006) Comparative analysis
of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose
tissue. Stem Cells 24: 1294–1301.
5. Hattori H, Sato M, Masuoka K, Ishihara M, Kikuchi T, et al. (2004) Osteogenic
potential of human adipose tissue-derived stromal cells as an alternative stem cell
source. Cells Tissues Organs 178: 2–12.
6. Majors AK, Boehm CA, Nitto H, Midura RJ, Muschler GF (1997)
Characterization of human bone marrow stromal cells with respect to
osteoblastic differentiation. J Orthop Res 15: 546–557.
7. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, et al. (1999) Mul-
tilineage potential of adult human mesenchymal stem cells. Science 284: 143–147.
8. Seong JM, Kim BC, Park JH, Kwon IK, Mantalaris A, et al. (2010) Stem cells in
bone tissue engineering. Biomed Mater 5: 062001.
9. Akagawa KS, Takasuka N, Nozaki Y, Komuro I, Azuma M, et al. (1996)
Generation of CD1+RelB+ dendritic cells and tartrate-resistant acid phospha-
tase-positive osteoclast-like multinucleated giant cells from human monocytes.
Blood 88: 4029–4039.
10. Ash P, Loutit JF, Townsend KM (1980) Osteoclasts derived from haematopoi-
etic stem cells. Nature 283: 669–670.
11. Scheven BA, Visser JW, Nijweide PJ (1986) In vitro osteoclast generation from
different bone marrow fractions, including a highly enriched haematopoietic
stem cell population. Nature 321: 79–81.
12. Martin TJ, Quinn JM, Gillespie MT, Ng KW, Karsdal MA, et al. (2006)
Mechanisms involved in skeletal anabolic therapies. Ann N Y Acad Sci 1068:
458–470.
13. Tang Y, Wu X, Lei W, Pang L, Wan C, et al. (2009) TGF-beta1-induced
migration of bone mesenchymal stem cells couples bone resorption with
formation. Nat Med 15: 757–765.
14. Chang MK, Raggatt LJ, Alexander KA, Kuliwaba JS, Fazzalari NL, et al. (2008)
Osteal tissue macrophages are intercalated throughout human and mouse bone
lining tissues and regulate osteoblast function in vitro and in vivo. J Immunol
181: 1232–1244.
15. Winkler IG, Sims NA, Pettit AR, Barbier V, Nowlan B, et al. (2010) Bone
marrow macrophages maintain hematopoietic stem cell (HSC) niches and their
depletion mobilizes HSCs. Blood 116: 4815–4828.
16. Alexander KA, Chang MK, Maylin ER, Kohler T, Muller R, et al. (2011)
Osteal macrophages promote in vivo intramembranous bone healing in a mouse
tibial injury model. J Bone Miner Res 26: 1517–1532.
17. Walsh NC, Reinwald S, Manning CA, Condon KW, Iwata K, et al. (2009)
Osteoblast function is compromised at sites of focal bone erosion in
inflammatory arthritis. J Bone Miner Res 24: 1572–1585.
18. Hodge JM, Kirkland MA, Aitken CJ, Waugh CM, Myers DE, et al. (2004)
Osteoclastic potential of human CFU-GM: biphasic effect of GM-CSF. J Bone
Miner Res 19: 190–199.
19. Aitken CJ, Hodge JM, Nishinaka Y, Vaughan T, Yodoi J, et al. (2004)
Regulation of human osteoclast differentiation by thioredoxin binding protein-2
and redox-sensitive signaling. J Bone Miner Res 19: 2057–2064.
20. Hodge JM, Kirkland MA, Nicholson GC (2007) Multiple roles of M-CSF in
human osteoclastogenesis. J Cell Biochem 102: 759–768.
21. Quinn JM, Elliott J, Gillespie MT, Martin TJ (1998) A combination of osteoclast
differentiation factor andmacrophage-colony stimulating factor is sufficient for both
human and mouse osteoclast formation in vitro. Endocrinology 139: 4424–4427.
22. Guihard P, Danger Y, Brounais B, David E, Brion R, et al. (2012) Induction of
osteogenesis in mesenchymal stem cells by activated monocytes/macrophages
depends on oncostatin M signaling. Stem Cells 30: 762–772.
23. Nicolaidou V, Wong MM, Redpath AN, Ersek A, Baban DF, et al. (2012)
Monocytes induce STAT3 activation in human mesenchymal stem cells to
promote osteoblast formation. PLoS One 7: e39871.
24. Quinn JM, Sims NA, Saleh H, Mirosa D, Thompson K, et al. (2008) IL-23
inhibits osteoclastogenesis indirectly through lymphocytes and is required for the
maintenance of bone mass in mice. J Immunol 181: 5720–5729.
25. Mosser DM (2003) The many faces of macrophage activation. J Leukoc Biol 73:
209–212.
26. Quinn JM, Morfis M, Lam MH, Elliott J, Kartsogiannis V, et al. (1999)
Calcitonin receptor antibodies in the identification of osteoclasts. Bone 25: 1–8.
27. Stanford CM, Jacobson PA, Eanes ED, Lembke LA, Midura RJ (1995) Rapidly
forming apatitic mineral in an osteoblastic cell line (UMR 106-01 BSP). J Biol
Chem 270: 9420–9428.
28. Korchynskyi O, ten Dijke P (2002) Identification and functional characterization
of distinct critically important bone morphogenetic protein-specific response
elements in the Id1 promoter. J Biol Chem 277: 4883–4891.
29. Allan EH, Hausler KD, Wei T, Gooi JH, Quinn JM, et al. (2008) EphrinB2
regulation by PTH and PTHrP revealed by molecular profiling in differentiating
osteoblasts. J Bone Miner Res 23: 1170–1181.
30. Passlick B, Flieger D, Ziegler-Heitbrock HW (1989) Identification and
characterization of a novel monocyte subpopulation in human peripheral
blood. Blood 74: 2527–2534.
31. Tacke F, Randolph GJ (2006) Migratory fate and differentiation of blood
monocyte subsets. Immunobiology 211: 609–618.
32. Song HY, Jeon ES, Kim JI, Jung JS, Kim JH (2007) Oncostatin M promotes
osteogenesis and suppresses adipogenic differentiation of human adipose tissue-
derived mesenchymal stem cells. J Cell Biochem 101: 1238–1251.
33. Delmas PD, Vergnaud P, Arlot ME, Pastoureau P, Meunier PJ, et al. (1995) The
anabolic effect of human PTH (1–34) on bone formation is blunted when bone
resorption is inhibited by the bisphosphonate tiludronate–is activated resorption
a prerequisite for the in vivo effect of PTH on formation in a remodeling system?
Bone 16: 603–610.
34. Walker EC, McGregor NE, Poulton IJ, Solano M, Pompolo S, et al. (2010)
Oncostatin M promotes bone formation independently of resorption when
signaling through leukemia inhibitory factor receptor in mice. J Clin Invest 120:
582–592.
35. Walker EC, Poulton IJ, McGregor NE, Ho PW, Allan EH, et al. (2012)
Sustained RANKL response to parathyroid hormone in oncostatin M receptor-
deficient osteoblasts converts anabolic treatment to a catabolic effect in vivo.
J Bone Miner Res 27: 902–912.
36. Minehata K, Takeuchi M, Hirabayashi Y, Inoue T, Donovan PJ, et al. (2006)
Oncostatin m maintains the hematopoietic microenvironment and retains
hematopoietic progenitors in the bone marrow. Int J Hematol 84: 319–327.
37. Sims NA, Jenkins BJ, Quinn JM, Nakamura A, Glatt M, et al. (2004)
Glycoprotein 130 regulates bone turnover and bone size by distinct downstream
signaling pathways. J Clin Invest 113: 379–389.
38. Sims NA (2009) gp130 signaling in bone cell biology: multiple roles revealed by
analysis of genetically altered mice. Mol Cell Endocrinol 310: 30–39.
39. Saleh H, Eeles D, Hodge JM, Nicholson GC, Gu R, et al. (2011) Interleukin-33,
a target of parathyroid hormone and oncostatin m, increases osteoblastic matrix
mineral deposition and inhibits osteoclast formation in vitro. Endocrinology 152:
1911–1922.
Macrophages Regulate Osteoblastic Maturation
PLOS ONE | www.plosone.org 13 September 2013 | Volume 8 | Issue 9 | e73266
